Loading...
Loading...
AbbVie
today
announced that results from part one of the Phase 2 portion of its Phase2/3
open-label study, TURQUOISE-I, in genotype 1 chronic hepatitis C patients with
human immunodeficiency virus type 1 (HIV-1) co-infection were published online
in The Journal of the American Medical Association (JAMA). Additional
sub-analyses also will be presented in both oral and poster presentations on
Feb. 26, at the Annual Conference on Retroviruses and Opportunistic Infections
(CROI) in Seattle, Wash.
As published today in JAMA, and originally presented at The Liver Meeting®
2014, the TURQUOISE-I study showed patients co-infected with genotype 1 (GT1)
hepatitis C virus (HCV) and HIV-1 receiving VIEKIRA PAK™ and ribavirin (RBV)
for 12 weeks or 24 weeks achieved sustained virologic response rates 12 weeks
post-treatment (SVR[12]) of 94 percent (n=29/31) and 91 percent (n=29/32),
respectively. The SVR[12] rates were 91 percent (n=51/56) for subjects with
HCV GT1a infection and 100 percent (n=7/7) for those with HCV GT1b infection.
"It is common for people to live with both GT1 chronic HCV and HIV, but data
supporting treatment of chronic HCV in these co-infected patients have been
limited," said Michael Severino, M.D., executive vice president, research and
development and chief scientific officer, AbbVie. "TURQUOISE-I is one of the
few dedicated studies looking specifically at this historically
difficult-to-treat population and we are proud to offer the HCV community an
important new treatment option."
VIEKIRA PAK is contraindicated with efavirenz (Sustiva) because
co-administration is poorly tolerated and results in liver enzyme elevations.
The ritonavir component of VIEKIRA PAK is an HIV-1 protease inhibitor and can
select for HIV-1 protease inhibitor resistance. To reduce this risk, HCV/HIV-1
co-infected patients should also be on a suppressive antiretroviral (ART) drug
regimen. The most common adverse events occurring in at least 10 percent of
patients in TURQUOISE-I were fatigue (48%), insomnia (19%), nausea (17%),
headache (16%), itching (13%), cough (11%), irritability (10%), and yellowing
of the eyes (10%).
Sub-analyses of these data will be presented later this week at CROI in oral
and poster presentations:
o High SVR Regardless of Time to Suppression with Paritaprevir/r/Ombitasvir
& Dasabuvir + RBV
Oral Presentation #147
February 26, 2015, 10:30-10:45 p.m. PST, Room 6AB
Analysis of time to HCV suppression in HCV/HIV co-infected patients in
TURQUOISE-I
o Hematologic Analysis of Paritaprevir/r/Ombitasvir and Dasabuvir + RBV in
TURQUOISE-I
Poster #691
February 26, 2015, 2:30-4 p.m. PST, Poster Hall
In this analysis of the TURQUOISE-I study, certain laboratory values in
patients taking paritaprevir/r/ombitasvir and dasabuvir with RBV were
examined, including hemoglobin, CD4+ T cells, and lymphocyte count
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in